Dudediligence.

Aura Biosciences, Inc

AURANASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

103.5M

on 2026-06-30, from 49.5M on 2024-03-31 10-Q ↗

a raise that quarter, at its price

25M50M75M100MMar2024JunSepDecMar2025JunSepDecMar2026Jun$6.00

Newest

$500.0M

S-3 of 2026-08-11. Sales under the at-the-market programme filed with it are not stated apart. S-3 ↗

$200.0M

Jefferies, agreement of 2026-08-11. No at-the-market sales statement read from a 10-Q or 10-K. S-3 ↗

Warrants

11.17M

Warrants of every class as tagged in the XBRL facts on 2026-06-30. 10-Q ↗

Cash

2.6 quarters

$67.8M on 2026-06-30 ÷ $25.8M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
DateWhatSharesPriceGrossFiling
2026-05-04Public offering incl. 3.80M pre-funded43,391,000$6.00$260.3M424B5 ↗